Cogstate Ltd · ASX:CGS
Cogstate — Shareholder Meeting (February 2006)
12 slides from Cogstate's shareholder meeting presentation, Feb 22, 2006
Slide 1: CogState EGM 22 February 2006
CogState aU, EGM 22 February 2006
Slide 2: Corporate overview
ee 1 Corporate overview
Slide 3: CogState specialises in development and commercialisation of rapid computerised cognitive tests
oa CogState specialises in the development and commercialisation of rapid, computerised diagnostic tests of cognition (brain function). Primary Market: The tests are sold to pharmaceutical, biotechnology, neutraceutical and functional food companies to quantify the effect of drugs or other intervent
Slide 4: Value proposition
ee Value proposition * — Sales growth from contracts with big pharma and food companies - Generating significant revenue deals + Attracted world class partners - Pfizer, Centres for Disease Control (USA), ALZA Corporation (a member of the Johnson & Johnson group) and Organon USA + Breadth and qualit
Slide 5: Recent announcements
ee Recent announcements * 1:7 fully underwritten non-renounceable rights issue * $400,000 revenue from nutraceutical trial deal ¢ $1.28 million Pfizer deal to accelerate portfolio development * $300,000 share placement through Taylor Collison New appointments « Ex-Pfizer scientist, Dr Peter Snyder a
Slide 6: Commercialisation strategy
ee 2 Commercialisation strategy
Slide 7: Commercialisation strategy
ee Commercialisation strategy ¢ Build relationships with world-class partners — Specifically target 4-5 big pharmaceutical companies with central nervous system technologies * Focus on generating revenue — Clinical trial market represents 80% of company revenue * Expand further into US and UK clinic
Slide 8: Company financials
ee 3 Company financials
Slide 9: Half year financial statements
ee Half year financial statements Half year Full year ended ended 31 Dec 04 30 June 05 Sales - Clinical trials $ 399,659 $ 839,998 $ 117,440 $ 144,655 $ 16,171 $41,117 - Concussion management - CogHealth - Funded R&D Grants - $ 67,608 $46,106} $221,761 - Export market development grant - Biotechnolo
Slide 10: Revenue growth
ee Revenue growth 500,000 400,000 “300,000 Sales 200,000 100,000 it! 200.4. ™2005 +695% +38% +85% +770% Jan - Mar Apr - Jun Jul - Sep Oct - Dec Cognitive test clinical trial market makes up 80% of revenue 10
Slide 11: Contracted future revenue
ee Contracted future revenue Contracted future revenue is defined as future revenue from signed contracts, not invoiced * Revenue to date does not include in excess of $2m in contracted future revenue — $0.8m to be recognised before year ended 30 June 2006 — A further $0.7m to be recognised before y
Slide 12: Brad O'Connor, Chief Executive Officer
| ie Brad O’Connor Chief Executive Officer CogState Ph: 03 9664 1300 boconnor@cogstate.com 12